Market Intelligence, Clinical Progress, and High-Purity Reagents for MTAP-Deleted Cancer Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MTAP drug discovery and the MTAP-deleted synthetic lethality pathway. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MTAP Recombinant Protein (Human, His-Tag) High purity (>95%), Endotoxin controlled. Sequence Verified by LC-MS. Suitable for enzymatic profiling and antibody screening. |
View MTAP Products |
| Gene Delivery | MTAP Promise-ORF / Lentivirus Particles Full-length human MTAP ORF for stable cell line construction to rescue MTAP-deleted phenotypes. |
View MTAP Products |
| Benchmark Ab | Anti-MTAP Recombinant Antibody High-affinity positive control for IHC, Western Blot, and ELISA assay validation. |
View MTAP Products |
| Validator | MTAP siRNA Set Target-specific siRNA pool for transient knockdown verification in control cell lines. |
View MTAP Products |
| Related Target A | PRMT5 Recombinant Protein & Assay Kits Key synthetic lethal partner. MTAP deletion leads to MTA accumulation, selectively sensitizing cells to MTA-cooperative PRMT5 inhibitors. |
View PRMT5 Products |
| Related Target B | MAT2A Recombinant Protein & Assay Kits Methionine Adenosyltransferase 2A. Targeting MAT2A depletes SAM, synergizing with PRMT5 inhibition in MTAP-deleted tumors. |
View MAT2A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting MTAP-deficient status selectively | Isogenic cell line validation tools (MTAP Lentivirus for rescue lines) strictly sequence-verified. |
| High-throughput screening of MTA-cooperative inhibitors | High-purity, low-endotoxin PRMT5 and MAT2A protein complexes to model the MTAP-deleted metabolic state. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Knockdown Studies | Multi-sequence pooled siRNA sets included for high-specificity gene silencing checks |
Live MTAP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for targeting MTAP-deleted cancers is intensifying, with major players shifting focus from traditional non-selective methyltransferase inhibitors to next-generation MTA-cooperative PRMT5 inhibitors and MAT2A inhibitors. Because MTAP (Methylthioadenosine Phosphorylase) is homozygous deleted in approximately 15% of all human cancers (co-deleted with CDKN2A on chromosome 9p21), it represents one of the most validated targets for synthetic lethality. As first-generation therapies reach the clinic, the next wave of R&D is targeting the metabolic vulnerabilities created by the accumulation of methylthioadenosine (MTA), driving demand for highly specific screening assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| MTA-Cooperative PRMT5 Inhibitors | Amgen, Mirati Therapeutics (BMS), Tangent Therapeutics | Solid Tumors (NSCLC, Glioblastoma, Pancreatic Cancer) | Enzymatic assays requiring high-purity PRMT5/MEP50 complexes and MTAP-deficient control cell lines. |
| MAT2A Inhibitors | Ideaya Biosciences, Servier | MTAP-deleted Solid Tumors, Lymphoma | SAM/SAH quantification assays and high-purity MAT2A recombinant enzymes. |
| Diagnostic Antibodies (IHC) | Ventana (Roche), Cell Signaling Technology | Patient Stratification / Companion Diagnostics | High-affinity, sequence-verified MTAP recombinant proteins for antibody validation and IHC assay development. |